Is ACADIA Pharmaceuticals Inc. (ACAD) Price Targeted To Increase?


As of Friday close, ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) stock was down -$0.82, moving down -3.98 percent to $19.80. The average number of shares traded per day over the past five days has been 3,714,500 shares. 3 times new highs have been achieved over the past 5 days, with a -$0.57 fall in that time frame. In the last twenty days, the average volume was 2,267,155, while in the previous 50 days, it was 1,645,210.

Since last month, ACAD stock rose 4.38%. Shares of the company fell to $18.60 on 02/23/23, the lowest level in the past month. A 52-week high of $28.06 was reached on 02/28/23 after having rallying from a 52-week low of $12.24. Since the beginning of this year, ACAD’s stock price has risen by 24.37% or $3.88, and marked a new high 12 times. However, the stock has declined by -29.42% since its 52-week high.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


ACAD stock investors should be aware that ACADIA Pharmaceuticals Inc. (ACAD) stock had its last reported insider trading activity 22 days ago on Feb 24. DAVIS STEPHEN, the CEO of the company, disposed of 3,851 shares for $18.78 on Feb 24. It resulted in a $72,322 divestment by the insider. KIM AUSTIN D. sold 803 shares at an average price of $18.78 on Feb 24. The insider now owns 20,108 shares following the transaction. On Feb 24, EVP, Chief Financial Officer Schneyer Mark C. sold 577 shares at $18.78 apiece. The transaction was valued at $10,836.

Valuation Metrics

The stock’s beta is 0.56. Besides these, the trailing price-to-sales (P/S) ratio of 6.25, the price-to-book (PB) ratio of 8.02.

Financial Health

In the three months ended December 30, ACADIA Pharmaceuticals Inc.’s quick ratio stood at 4.00, while its current ratio was 4.00, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 98.00% percent. In the year ended December 30, operating margins totaled -43.20%. Based on annual data, ACAD earned $507.07 million in gross profit and brought in $517.24 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -56.50%. Return on equity (ROE) for the past 12 months was -50.60%.

According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ACAD’s revenue rose 4.2% to $130.71 million during the quarter, while net income inched up to $136.49 million. While analysts expected ACADIA Pharmaceuticals Inc. to report -$0.24 quarterly earnings, the actual figure was -$0.26 per share, beating the consensus estimate by -8.30%. During the quarter, the company generated -$47.67 million in EBITDA. The liabilities of ACADIA Pharmaceuticals Inc. were 187.4 million at the end of its most recent quarter ended December 30, and its total debt was $62.0 million. The value of shareholders’ equity is $162.23 million.

Technical Picture

This quick technical analysis looks at ACADIA Pharmaceuticals Inc.’s (ACAD) price momentum. With a historical volatility rate of 50.30%, the RSI 9-day stood at 47.49% on 17 March.

With respect to its five-day moving average, the current ACADIA Pharmaceuticals Inc. price is down by -2.80% percent or -$0.57. At present, ACAD shares trade +5.83% above its 20-day simple moving average and +24.69% percent above its 100-day simple moving average. However, the stock is currently trading approximately +15.79% above its SMA50 and +15.93% above its SMA200.

Stochastic coefficient K was 43.31% and Stochastic coefficient D was 43.92%, while ATR was 0.96. Given the Stochastic reading of 34.08% for the 14-day period, the RSI (14) reading has been calculated as 50.34%. As of today, the MACD Oscillator reading stands at -0.14, while the 14-day reading stands at -0.26.

With a median target price of $21.00, the current consensus forecast for the stock is $12.00 – $33.00. Based on these forecasts, analysts predict ACADIA Pharmaceuticals Inc. (ACAD) will achieve an average price target of $22.32.


Please enter your comment!
Please enter your name here